Objectives: To measure persistence and nonrecurrence of depression treatment and investigate potential risk factors.
. We searched for studies following patients for ≥4 years with ≥3 follow-up measurements and found clinical studies recruiting in primary care (Riihimäki, Vuorilehto, Melartin, & Isometsa, 2014) , secondary care (Furukawa, Kitamura, & Takahashi, 2000; Holma, Holma, Melartin, Rytsala, & Isometsa, 2008; Kanai et al., 2003; Keller et al., 1992; Maj, Veltro, Pirozzi, Lobrace, & Magliano, 1992; Mueller et al., 1999; Solomon et al., 1997) , and tertiary care (Naz et al., 2007) . One German survey followed inpatients for 3 years after discharge (Seemuller et al., 2014) .
These and similar "clinical cohorts" provide landmark measures of depression persistence or recurrence but cannot avoid methodological shortcomings such as selectivity by setting, Bergson's bias, (differential) recall bias, Hawthorne effect, and attrition. Sample sizes ranged from n = 87 (Naz et al., 2007) to n = 431 (Keller et al., 1992) . This limits detailed multivariate analysis, especially of infrequent explanatory variables (Lee, 2003) . Associations of gender or further variables with depression persistence/recurrence were frequently not conclusive across studies (Hardeveld et al., 2010; Steinert et al., 2014a; van Weel-Baumgarten, Schers, et al., 2000) .
Representative studies with a large sample, longterm follow-up, and close measurement are hardly feasible and expensive (Cochran & Chambers, 1965) . We decided on a retrospective approach and discuss limitations of this (Hemkens, Contopoulos-Ioannidis, & Ioannidis, 2016) . The Institute for Quality and Efficiency in Healthcare (IQWiG, 2013 ) and the BARMER GEK statutory health insurance (SHI) provided resources and claims data to analyse treatment patterns in Germany.
Our first objective was to analyse depression treatment in each quarter for 16 quarters and to measure
• the proportion of patients with continual treatment (longterm persistence);
• the proportion of patients who stop and never resume treatment (longterm nonrecurrence);
• the median/average time to first treatment discontinuation;
• the proportion of total time spent having treatment.
Our second objective was to identify variables associated with longterm persistence and nonrecurrence from baseline sociodemographic and depression treatment data.
2 | METHODS
| Design
We performed a retrospective follow-up study of a population-based We analysed billed inpatient/outpatient-services related to a depression diagnosis (F32.x/F33.xICD-10), and outpatient antidepressant prescriptions (ATC-code N06Axx) per patient and quarter of the year (Sections 2.4 and 2.5). A patient's first quarter of observation was defined by the first depression-related service in 2007. We traced each patient for 16 quarters (plus one to ascertain discontinuation).
We followed international (Benchimol et al., 2015; von Elm et al., 2007) and German (Swart et al., 2016) We defined a subgroup of persons for whom premerger data on "insurance status" and a German municipality key were available. For this subgroup, we had complete and comprehensive baseline data.
We used this subgroup for multivariate exploration of associations of baseline variables ( Figure 1i , Table 1b, Table 3 ).
Physicians in Germany code outpatient diagnoses as "ruled out", "asymptomatic", "suspected", and "confirmed". We analysed solely outpatient (inpatient) treatment files holding specified "confirmed" (main discharge) diagnoses (Gerste & Roick, 2014; Kleine-Budde et al., 2013) . The term "physician" includes medical/psychological psychotherapist.
| Study population
We included patients of any age with assured, newly diagnosed unipolar depression in 2007 (Townsend, Walkup, Crystal, & Olfson, 2012) according to a case definition (Gerste & Roick, 2014; IQWiG, 2013; Kleine-Budde et al., 2013; Spettell et al., 2003) .
We used diagnoses of "single depressive episode" (F32.0/1/2/8/ 9ICD-10) or "recurrent depression" (F33.0/1/2/8/9ICD-10) in 2007. We included patients if they had at least (case definition, Figure 1b) • two outpatient diagnoses by two physicians within one quarter,
• two outpatient diagnoses within two different quarters, or
• one inpatient diagnosis.
To ensure new-onset depression treatment, we excluded patients with ≥1 preexisting outpatient or inpatient depression diagnosis (F32.
x/F33.xICD-10) in 2006 ( Figure 1c ). We did not exclude patients with antidepressant prescriptions in 2006 (ATC-code N06Axx) who had no coexisting depression diagnosis as these antidepressant prescriptions were possibly meant for other conditions (Melfi & Croghan, 1999 Figure 1d ). Beyond 2007, we excluded all patients newly diagnosed with F0/F1/F2/F5/F6/F7/F8/F9ICD-10 ( Figure 1f ). We did not exclude newly diagnosed "neurotic stress and somatoform disorders" (F4x.xICD-10), a diagnostic group that frequently overlaps with depression. We regarded it as "concomitant symptoms" of previously diagnosed depression (Silverstone & von Studnitz, 2003; Wiegand, Sievers, Schillinger, & Godemann, 2016) .
We excluded diagnosed psychiatric comorbidity in 2007 and beyond to exclusively analyse depression disease and avoid bias by psychiatric comorbidity and possible misclassification of outpatient psychiatric services (Section 2.4). Three outpatient categories were necessary because a quarter with a confirmed outpatient physician depression diagnosis does not necessarily reflect ongoing treatment of depression. The diagnosis might not be valid (Mitchell, Vaze, & Rao, 2009 • "Psychotherapy or specialist interview" (PT/SI) comprised service codes marking a psychotherapy session or neurological/psychiatric/medical-specialist interventions ≥10 min.
| Identifying and classifying depression treatment
• "Other services" covered, for example, anamnesis; tests; training procedures; electroencephalogram, mostly provided by medical specialists, or psychotherapy report; probatory session; and urgent home visit provided by general practitioner, specialist, or psychotherapist.
• "No other services" defined minimum observed outpatient physician "treatment" by absence of any specified depressionrelated service code and only one physician noting the diagnosis. German physician associations use a fee-for-service system and a comprehensive list of single service codes to distribute SHI payments.
To analyse treatment and costs related to depression disease, the Institute for Quality and Efficiency in Health Care specified a sample list of service codes for a cost-effectiveness report on antidepressants (IQWiG, 2013) . Service codes were extracted for a trial sample solely diagnosed with depression, ranked by frequency per physician group, and independently reviewed by physician/economist. We used this list for classification. A senior medical specialist further deleted a few service codes ambiguously signalling low-threshold maintenance therapy.
Service codes (see Supporting Information) were tested for annual consistency using frequency analysis.
Physician and SHI Association's data transfer agreements limit diagnosis validation in the same quarter (Zeidler et al., 2013) We followed methodological considerations on data-based episode construction (Hornbrook et al., 1985; Kessler, Steinwachs, & Hankin, 1980; Wingert, Kralewski, Lindquist, & Knutson, 1995) .
| Defining outcomes
Longterm-DTPQ-persistence gives the number of patients with 16 + 1 consecutive quarters of DTPQ-continuation as opposed to patients with 16 or less quarters. Total-time-spent-with-DTPQ gives the possible intermittent number of DTPQ within first 16 quarters.
Longterm-DTPQ-nonrecurrence

| Baseline patient characteristics
We classified each patient's baseline level of severe (F32.2/F33.2), F32.9/F33.9) depression and recurrence (F33.x) by the most severe outpatient/inpatient diagnosis in the first new-onset DTPQ and three subsequent quarters (Table 1e) . We chose four quarters to obtain a sustainable assessment of maximum severity (Kleine-Budde et al.,
2013).
We hierarchically assigned five categories of baseline treatment:
"hospital" treatment, "psychotherapy/specialist-interview and antidepressants," "psychotherapy/specialist-interview," "antidepressants,"
and "other" services (Table 1e ). For this, we assigned each patient's most intense category of depression treatment (Section 2.4, Figure 2 TABLE 3 Logistic regression models for longterm-DTPQ-persistence/nonrecurrence (subgroup) d) in the first new-onset DTPQ and one subsequent quarter (Boenisch et al., 2011; Heggestad, Lilleeng, & Ruud, 2011) . We used two quarters as solely the first DTPQ might not adequately reflect subsequent transfers to specialised care (Gerste & Roick, 2014) .
| Statistical analysis
We used Wilcoxon rank-sum tests to assess mean differences in timeto first-DTPQ-discontinuation and total-time-spent-with-DTPQ. We assumed a full 3 months of observation time per quarter to compare results reported per month.
We used logistic regression to identify variables associated with longterm-DTPQ-persistence or longterm-DTPQ-nonrecurrence. We built a model using depression disease characteristics and sociodemographic variables as available in German claims data. Previous multivariate models based on German claims data explored associations with depression outcomes (Bramesfeld, Grobe, & Schwartz, 2010; KleineBudde et al., 2013; Wagner et al., 2016) . We selected a comprehensive list of explanatory variables from these models and other models using survey data (Colman et al., 2011; Dowrick et al., 2011; Meyers et al., 2002; Viinamaki et al., 2006) . To explore associations, we used the same set of explanatory variables for both outcomes.
We controlled for the calendrical first new-onset DTPQ as this variable is subject to seasonality and represents a "sampling weight" reflecting selection bias induced by the cross-sectional year 2007 depression case definition (Höfler, Lieb, & Wittchen, 2007;  Section 2.3).
The case definition criterion "two outpatient diagnoses within two different quarters" reduced the number of patients eligible per calendrical quarter in 2007 (Table 1e ). This "skewness" reflects two factors associated with outcomes: First, patients selected in 2007quarter4 could only meet the criteria "one inpatient diagnosis" or "two outpatient diagnoses by two physicians within one quarter." They had more intense treatment than many patients selected in 2007quarter1 where just one physician diagnosis-validated later on-sufficed. Second, 2007quarter1 comprises the most "quarter-combinations" permitting a gap for physician diagnosis validation and thus the highest inherent probability for early DTPQ-discontinuation defined by a one-quarter gap.
Analysis was performed with SAS Version 9.2. Results were considered statistically significant for p values <.05.
3 | RESULTS
| Study population
We identified 28,348 newly diagnosed patients; 80.9% were female (Table 1c) . Mean age at baseline was 48.9 years (SD 15.1, range 8- 48.8% of patients were diagnosed solely with "unspecified/atypical" depression (F32.8/F33.8/F32.9/F33.9). Recurrent depression was diagnosed in 22.5% of patients (Table 1e ).
The subgroup for multivariate analysis had more females (83.0% vs.
80.9%) and a higher mean age (49.8 vs. 48.9). There was no relevant difference in depression disease-related characteristics (Table 1a ,b), longterm-DTPQ-persistence, and longterm-DTPQ-nonrecurrence (Table 2c ,d, Table 3 ).
| Longterm-DTPQ-persistence and associated variables
Of identified patients, 13.7% had longterm-DTPQ-persistence for 16 + 1 quarters (Study population, Table 2c ). Our multivariate model showed the following (subgroup, Table 3a , p < .001 where not stated otherwise):
The likelihood of longterm-DTPQ-persistence increased per year of age (+3.3%), and for
• patients with a baseline period of unemployment (+20.8%, p = .012, reference group "employed"),
• retirees (+31.1%, reference group "employed"),
• patients insured as a dependent (+32.3%, reference group "employed"),
• residents in East Germany (+17.6%, p = .009),
• a rural area (+10.3%, p = .060),
• patients with baseline treatment category "hospital" (+79.7%, ref-
erence group "other" services),
• patients with baseline treatment category "psychotherapy/specialist-interview and antidepressants" (+81.4%, reference group "other" services).
The likelihood of longterm-DTPQ-persistence decreased for
• areas with a low number of psychotherapists (−15.6%, p = .009),
• patients diagnosed with mild depression (−29.2%, reference group unspecified/atypical depression).
| Longterm-DTPQ-nonrecurrence and associated variables
Among 17,970 patients with up to four consecutive DTPQ at the beginning of observation, 34.1% had longterm-DTPQ-nonrecurrence (Study population, Table 2d ). Our multivariate model showed the following (Subgroup , Table 3b , p < .001 where not stated otherwise):
The likelihood of longterm-DTPQ-nonrecurrence increased for
• retirees (+17.5%, p = .004, reference group "employed"),
• patients diagnosed with mild depression (+14.8%, p = .046, reference group unspecified/atypical depression),
• patients with baseline "psychotherapy/specialist-interview"
(+39.8%, reference group "other" services).
The likelihood of longterm-DTPQ-nonrecurrence decreased per year of age (−1.2%), and for
• females (−16.4%),
• patients insured as a dependent (−12.1%, p = .028, reference group "employed"),
• patients with baseline treatment category "antidepressants"
(−45.9%, reference group "other" services).
3.4 | Time-to-first-DTPQ-discontinuation
Median (mean) time-to-first-DTPQ-discontinuation was 3 quarters/ 9 months (5.4 quarters/~16.3 months) within 16 quarters of follow-up (Table 2a) . Following a bimodal distribution (Supporting Information), 63% of patients (n = 17,970, Table 2d , Figure 3 ) discontinued within year one, and 13.7% never discontinued within 16 + 1 quarters (Table 2c) . On average, patients aged ≥65 years took about one quarter longer to DTPQ-discontinuation. We found no significant gender difference.
| Total-time-spent-with-DTPQ
Within 16 quarters, patients spent, on average, 54.3%/8.7 quarters/ 26.0 months with defined depression treatment (Table 2b , Figure 2 d1-d16, Section 2.5). Patients aged ≥65 years spent more total-timewith-DTPQ (61.4%). Males spent less total-time-with-DTPQ (51.6%).
| DISCUSSION
We retrospectively traced 4 years of utilisation data. Fourteen percent (34%) of identified patients had longterm-DTPQ-persistence (longterm-DTPQ-nonrecurrence). This was comparable to depression symptom measures reported by prospective surveys.
To check plausibility of longterm-DTPQ-persistence, we selected four studies (Holma et al., 2008; Keller et al., 1992; Riihimäki et al., 2014; Solomon et al., 1997) , best possibly matching follow-up-time, using close follow-up measurement at least after month 6/18/60, and Longitudinal-Internal-Follow-up-Evaluation-Methodology (Keller et al., 1987) for unipolar depression (n > 100) treated at baseline (Dintsios & Wagner, 2017 ; Figure 3 ). For longterm-DTPQ-(non)-recurrence, we selected three studies (Holma et al., 2008; Kanai et al., 2003; Kennedy & Paykel, 2004 ) that closely fitted these criteria.
| Treatment measures versus symptom measures
Surveys differently measured "discontinuation of depression symptoms." The Finnish surveys (Holma et al., 2008; Riihimäki et al., 2014) defined "absence of any depression symptoms" (full-remission-definition). The U.S. surveys (Keller et al., 1992; Solomon et al., 1997) defined "absence of major depression tolerating residual symptoms"
(tolerant-recovery-definition). It takes longer to reach full-remissiondefinition than tolerant-recovery-definition. This difference matters in comparisons.
Fourteen percent of patients had longterm-DTPQ-persistence. Surveys reported Kaplan-Meier-estimators of 27% (Riihimäki et al., 2014) , 13% (Holma et al., 2008) , 13% (Keller et al., 1992) , and 9% ( Consistent with differing definitions of discontinuation, time-tofirst-discontinuation and longterm persistence were highest for the Finnish studies (full-remission-definition) followed by our study (DTPQ), and lowest for the U.S. studies (tolerant-recovery-definition).
We found 34.1% of patients with longterm-DTPQ-nonrecurrence within 3 years. Surveys estimated higher proportions of patients with symptoms-nonrecurrence (taken from Kaplan-Meier curves):
• 40%, Finland, nonrecurrence of "major-depressive-episode,"
4 years (Holma et al., 2008 );
• 41%, England, nonrecurrence of "major-depressive-episode,"
3 years (Kennedy & Paykel, 2004 );
• 42%, Japan, nonrecurrence of "subthreshold depression," 4 years, n = 82, 20 lost to follow-up (Kanai et al., 2003) .
A DTPQ ( Patient's total-time-spent-with-DTPQ covered 54% of total observation time within 4 years. Similarly, patients spent "1%" and "20%" (Holma et al., 2008) , or "24%" and "34%" (Riihimäki et al., 2014) of their total observed person-time in "partial remission" and "major-depressive-episode" within 5 years.
Inversely, patients had 46% total-time-spent-without-DTPQ. This compared to 49% (Holma et al., 2008) and 42% (Riihimäki et al., 2014 ) of time-spent-in-full-remission. DTPQ-classification seemingly covers any person-time with "partial remission" and "major-depressive-episode," but nothing beyond "full remission."
Differences in outcomes are mainly explained by differing definitions for measuring depression symptoms. For raw plausibility comparison, we assume negligibility of regional differences (Wittchen et al., 2011 ) and subordination of sampling/design differences. Our sample underrepresented low-threshold outpatient care (Section 4.4.4). This might facilitate comparability of respectively selective samples (Figure 3 ).
We largely excluded diagnosed existing and upcoming psychiatric comorbidity (Figure 1d,f) . Surveys mostly excluded some relevant existing psychiatric comorbidity (Figure 3 ). Certain comorbidities possibly heterogeneously correlate with depression treatment or symptoms (Gijsen et al., 2001; Wagner et al., 2016) . We found good outcome comparability, despite comorbidity sampling differences. Heterogeneous effects of psychiatric comorbidity possibly might "somehow even out."
4.2 | Depression severity, sociodemographics, and longterm outcomes
Diagnosed unspecified/atypical depression showed a higher likelihood for longterm-DTPQ-persistence/recurrence than mild depression (Table 3a ,b). Mostly general practitioners code unspecified/atypical depression (Wagner et al., 2016) for uncertain cases requiring watchand-wait (Boenisch et al., 2011) . Uncertain cases persist/recur more often than specified mild ones. This seems plausible.
Women did not differ from men in the duration/chronification of ongoing treatment. Consistent with cited studies, female gender was not significantly associated with longterm-DTPQ-persistence (Beekman et al., 2001; Kessler, McGonagle, Swartz, Blazer, & Nelson, 1993) or time-to-first-DTPQ-discontinuation (Simpson, Nee, & Endicott, 1997 ).
However, women had more future periods of treatment. Female gender was associated with increased longterm-DTPQ-recurrence.
Likewise, Ernst and Angst (1992) reported more recurrence of symptoms below major-depressive-episode, but not for specific DSM-III-R-criteria. Mueller et al. (1999) reported more women with recurring "psychiatric-status-rating level 1-6" but not with full major-depressive-episode. More recurrence of symptoms below major-depressiveepisode confirmed more recurrence of assumingly "low-threshold" treatment.
Accordingly, women had more total-time-spent-with-DTPQ. Studies confirm this (Bracke, 2000; Winokur, Coryell, Keller, Endicott, & Akiskal, 1993) . More future "low-threshold" treatment might not specifically relate to depression disease. Women in Germany generally have more drug prescriptions (Stock, Stollenwerk, Redaelli, Civello, & Lauterbach, 2008) and physician visits (Gerste & Günster, 2014) .
Older age consistently showed a strong "deteriorating" association for all outcomes (van Weel-Baumgarten, Schers, et al., 2000) . Regionally low psychotherapist-density was significantly associated with decreased longterm-DTPQ-persistence. Supply shortage could possibly influence shorter treatment. However, low psychotherapist-density could equally indicate a "healthy" area (Jacobi et al., 2016) .
| Baseline treatment and longterm outcomes
Baseline treatment in "hospital" had a significant association with considerably increased longterm-DTPQ-persistence of ongoing treatment. Keller et al. (1984) confirmed this. "Hospital" was not significantly associated with future longterm-DTPQ-nonrecurrence. We found no comparable longitudinal evidence for verification.
Intense "psychotherapy/specialist-interview and antidepressants" treatment had a significant association with considerably increased chronification of ongoing treatment but not with recurrence of future treatment. The German guideline recommends combination therapy for acute severe episodes (AWMF, 2015) . Zobel et al. (2011) found more patients on controlled combination therapy with sustained remission in a 5-year randomised controlled trial (RCT) of inpatients. We found no such association in a population sample for noncontrolled combination treatment.
Baseline treatment reflects administered combination therapy by one physician but also patients who possibly successively visit more than one physician and possibly successively receive psychotherapist/specialist-interview and antidepressants. Rucci et al. (2011) reported more relapses within 6 months in patients requiring (subsequent) combination treatment to achieve remission. Some successive treatment "augmentation" might indicate problematic cases. These possibly require longer ongoing (specialist) treatment.
Baseline "psychotherapy/specialist-interview" was significantly associated with increased longterm-DTPQ-nonrecurrence. "Antidepressants" was significantly associated with decreased longterm-DTPQ-nonrecurrence. Neither was significantly associated with longterm-DTPQ-persistence of ongoing treatment.
Subgroup-proportions of longterm-DTPQ-nonrecurrence within 3 years compared to longterm meta-analyses: Among 4,660 patients with "antidepressants," 23.6% had longterm-DTPQ-nonrecurrence (Table 2d) . Among 119 patients with antidepressants, 40% had no recurrence within 1-2 years (Gloaguen, Cottraux, Cucherat, & Blackburn, 1998 ). Among 2,579 patients with "psychotherapy/specialistinterview," 47.8% had longterm-DTPQ-nonrecurrence (Table 2d ).
Among 1,880 patients receiving cognitive psychotherapy, 46% had no recurrence within 2 years (12/28 studies used major-depressiveepisode-criteria; Vittengl, Clark, Dunn, & Jarrett, 2007) . Numbers compared despite "low-threshold" inclusion of medical specialist interviews (Section 2.4).
RCT-results on longterm-effects of antidepressants on recurrence were not contradictory (Hughes & Cohen, 2009 Baseline "antidepressants" treatment was not significantly associated with longterm-DTPQ-persistence. Contradictory, Gilchrist and Gunn (2007) identified antidepressant use as a risk factor for persistence in 17 observational studies. However, 10/6/1 studies followed up below/exactly/beyond 12 months and frequently undercut a reasonable minimum cut-off-definition for "persistence" (Section 4.1, Table 2a , Supporting Information).
RCT-results on longterm effects of psychotherapy on recurrence were confirmatory (Steinert, Hofmann, Kruse, & Leichsenring, 2014b) . However, we did not strictly measure "psychotherapy," but included interviews ≥10 min by neurologist/psychiatrist/medical-specialists. Patients with new-onset diagnosed depression receiving "psychotherapy/specialist-interview" early on had a significantly increased likelihood of longterm-DTPQ-nonrecurrence.
We found seemingly good comparability to RCT-results. However,
we analysed "effectiveness" of crudely categorised ordinary clinical practice (hierarchy) without randomisation and only partial adjustment for confounding factors (Section 4.4.3). In real-world care, length of antidepressants use (Ufer et al., 2007) and dosage (Riedel-Heller, Matschinger, Schork, & Angermeyer, 2001; might sometimes undercut guideline recommendations. We assume possible short-time/low-dosage antidepressants use moderate the reported effect of "antidepressants treatment" (Melfi et al., 1998) .
Psychotherapy/medical specialist interventions are fully covered by SHI but not prescribed as easily as antidepressants. Patients need to enforce it and choose a therapist (IQWiG, 2016) . Characteristics (preferences) of patients (providers) selecting (assigning) psychotherapy early on appear to moderate longterm-DTPQ-nonrecurrence (Ioannidis, 2016; Schomerus et al., 2013) .
Intense baseline treatment in "hospital" or with "psychotherapist/ specialist-interview and antidepressants" possibly covers more "problematic cases" with, for example, difficult diagnostic clarification, therapy resistance, or acute endangerment of self/others (AWMF, 2015).
Confounding by "problematic cases" needs to be considered when interpreting baseline treatment ( Table 2, Table 3 ).
| Strengths, limitations, and generalisability
We consider the following as main strengths of our study:
• longterm, external, gapless measurement;
• a population-based sample including elderly patients;
• a sample size allowing for statistical inference especially on baseline treatment;
• restriction of data misclassification using data classification across providers and extensive exclusion of diagnosed psychiatric comorbidity (Schneeweiss et al., 2007) .
| Missing data
Psychiatric-outpatient-clinic data were not available. Psychiatric-outpatient-clinics care for a fraction of severely ill and mentally multimorbid patients (Spengler, 2003) , which we mostly excluded.
Assumingly negligible outcome underestimation occurred only when no same-quarter physician/hospital visit existed.
| Misclassification
Cross-provider-combinations mostly prohibited false-positive DTPQ (Figure 2d ). The least specific and most frequent DTPQ-class was "other depression-related services PQ" (Figure 2d16 ). From this, we excluded single-physician-diagnoses without service codes (Figure 2 d18). Still, false-positive DTPQ is detected when a confirmed depression diagnosis is wrongly retained/denoted and all selected service codes relate to coexisting physical illness. Comparably low outcomes for "other services" (Table 2) suggest that possible overestimation might be tolerable. The same holds for depression treatment with "other services" and "antidepressants" (Figure 2d15 , Table 2 ), which might partly reflect maintenance/prophylaxis treatment.
Among antidepressant users, 8.7% (n = 601) had their first prescription before their first diagnosis (Section 2.5). DTPQ-measurement began before diagnosed observations. Detection "inequality"
caused relative overestimation of time-to-first-DTPQ-discontinuation.
Longterm-DTPQ-persistence or longterm-DTPQ-nonrecurrence was assumingly not relevantly affected. Despite a subsequent diagnosis (Section 2.4), few of these patients still possibly used antidepressants for another indication (Melfi & Croghan, 1999) . Their DTPQ-onset was misclassified too early. They were possibly misclassified for "antidepressants." We assume this bias to be negligible among n = 6.948 classified antidepressant users.
| Residual confounding
Multivariate analysis lacked controls for "education" (Wittchen & Uhmann, 2010) , "physical illness" (Beekman et al., 2001) , "social support" (Leskela et al., 2004) , "low mastery" (Wittchen & Uhmann, 2010) , and "problematic cases" (AWMF, 2015) . Physicians seemingly frequently diagnose "F32.x," whereas patient history suggests "F33.x" (Wiegand et al., 2016) . Thus, we incompletely approximated relevant "previous episodes (F33.x)" (Steinert et al., 2014a) . Missing or incomplete variables suggest overt bias in our estimation of explanatory variables.
| Generalisability
Sample selectivity and design suggest overestimation of longterm-DTPQ-persistence, longterm-DTPQ-recurrence, time-to-first-DTPQ-discontinuation, and total-time-spent-with-DTPQ.
The case definition-criterion "two outpatient diagnoses within two different quarters in 2007" (Section 2.3, Figure 1b ) excluded "lowthreshold" patients with one-off diagnoses, inherently prolonged initial outcome measurement, and underrepresented primary care patients (Section 2.8).
We excluded 14% of patients dying, switching sickness fund, and going abroad (Figure 1e) . Excluding suicides or presumably more healthy/active patients generates persistence/recurrence overestimation.
Results comparison might suggest "overall comorbidity neutrality" (Section 4.1). However, we do not know whether our results hold for a majority of patients with existing/upcoming psychiatric comorbidity.
| Conclusion
Fourteen percent of patients never discontinued a defined minimum depression treatment for 16 + 1 quarters. Thirty-four percent never resumed depression treatment within 3 years. Depression treatment covered~54% of person-time within 4 years. Patients took three quarters or~9 months median time-to-first-discontinuation. This compared to landmark survey outcomes for "total symptoms absence" or "presence of at least residual symptoms," despite sampling differences.
The German Social Code Book IX for rehabilitation services defines disability as "six and more months of deviating health status. Multivariate analysis generated hypotheses about causation:
Women had more "episodic depression treatment" (longterm-DTPQrecurrence, total-time-spent-with-DTPQ) than men, possibly influenced by generally more frequent utilisation. Women differed not in "chronic depression treatment" (time-to-first-DTPQ-discontinuation, longterm-DTPQ-persistence). Being retired was equally associated with increased persistence and nonrecurrence. We suggest research/interventions for retirement transition and more detailed research on frequent early retirement.
Starting treatment intensely in "hospital" or with "psychotherapy/ specialist-interview and antidepressants" meant 1.8-fold likelihood of longterm-DTPQ-persistence but did not relevantly influence future longterm-DTPQ-nonrecurrence. We suggest secondary prevention interventions for incident intense users.
New-onset treatment with "antidepressants" ("psychotherapy/ specialist-interview") meant 0.54-fold (1.40-fold) likelihood of longterm-nonrecurrence of depression treatment. Possible short-time/ low-dosage antidepressants use and patient self-selectivity for psychotherapy/specialist-interview might moderate this partly adjusted longterm finding in real-world care.
We suggest further testing of longitudinal cross-provider-datalinkage to measure "treatment-free-time," especially stratified by comorbidity, to quantify this study's possible selectivity and possible misclassification by comorbidity.
